World Federation of Hemophilia/LinkedIn
Oct 30, 2025, 06:57
For People on Emicizumab, the Use of a aPCC Raises Critical Clinical Questions
World Federation of Hemophilia shared a post on LinkedIn:
“For people on emicizumab, the use of activated prothrombin complex concentrate (aPCC) raises critical clinical questions. A new article bridges evidence with real-world practice to guide safer, smarter care decisions.”
Title: Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice
Authors: Robert F. Sidonio, Jr., Guy Young, Carmen Escuriola Ettingshausen, Johnny Mahlangu, Margareth C. Ozelo, Alok Srivastava, Jerzy Windyga, Hye–Youn Lee, Aurelia Lelli, Steven W. Pipe
Read full article here.
Stay informed with Hemostasis Today.
activated prothrombin complex concentrate (aPCC)
Alok Srivastava
Aurelia Lelli
Carmen Escuriola Ettingshausen
Emicizumab
Guy Young
Health
Hematology
Hemostasis
Hemostasis Today
Hye–Youn Lee
Jerzy Windyga
Johnny Mahlangu
Jr.
Margareth C. Ozelo
Medicine
Robert F. Sidonio
rpth
Steven W. Pipe
World Federation of Hemophilia
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals